Patient views on mantle cell lymphoma research
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study asks people with mantle cell lymphoma about their views and experiences with clinical research. It aims to understand patient perspectives to help improve future trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with mantle cell lymphoma (a type of blood cancer).
- You don't have a serious medical or mental health condition that could interfere with the study.
- You are able to understand and sign a consent form.
- You are not currently participating in another treatment-focused clinical trial.
- You don't have an uncontrolled infection.
- You don't have a psychiatric or substance abuse disorder that would interfere with participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
This early-phase study tests a combination of venetoclax, lenalidomide, and rituximab in people newly diagnosed with mantle cell lymphoma. It aims to control the lymphoma and see how safe and effective this approach is for newly treated patients.
This trial tests a combination of three drugs (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma. The goal is to see if this combination works better for high-risk or older patients.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
This trial tests a combination of three medications (zanubrutinib, obinutuzumab, and sonrotoclax) for people with mantle cell lymphoma, a type of blood cancer. The goal is to see if this combination is safe and effective, and it may be an option for people who are older or have health issues that make a stem cell transplant too risky.
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.